No Data
Buy Rating for Mediwound Driven by EscharEx's Market Potential and Disruptive Role in Chronic Wound Care
Citi Initiates MediWound(MDWD.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Mediwound (MDWD) Receives a Buy From TD Cowen
Mediwound Advances in Enzymatic Therapeutics With Strategic Expansions
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate